The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Measles Virus for Cancer Therapy
Open accessAbstract
Measles virus offers an ideal platform from which to build a new generation of safe, effective oncolytic viruses. Occasional "spontaneous" tumor regressions have occurred during natural measles infections, but common tumors do not express SLAM, the wild-type MV receptor, and are therefore not susceptible to the virus. Serendipitously, attenuated vaccine strains of measles virus have adapted to use CD46, a regulator of complement activation that is expressed in higher abundance on human tumor cells than on their non transformed counterparts. For this reason, attenuated measles viruses are potent and selective oncolytic agents showing impressive antitumor activity in mouse xenograft models. The viruses can be engineered to enhance their tumor specificity, increase their antitumor potency and facilitate noninvasive in vivo monitoring of their spread. A major impediment to the successful deployment of oncolytic measles viruses as anticancer agents is the high prevalence of pre-existing anti measles immunity, which impedes bloodstream delivery and curtails intratumoral virus spread. It is hoped that these problems can be addressed by delivering the virus inside measles-infected cell carriers and/or by concomitant administration of immunosuppressive drugs. From a safety perspective, population immunity provides an excellent defense against measles spread from patient to carers and, in fifty years of human experience, reversion of attenuated measles to a wild type pathogenic phenotype has not been observed. Clinical trials testing oncolytic measles viruses as an experimental cancer therapy are currently underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem Cell Collection and Gene Transfer in Fanconi Anemia
Kelly, P. F., Radtke, S., Kalle, C. V., Balcik, B., Bohn, K., Mueller, R., Schuesler, T., Haren, M., Reeves, L., Cancelas, J. A., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300033 · Cited by 180
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationOncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Tumor Cell Marker PVRL4 (Nectin 4) Is an Epithelial Cell Receptor for Measles Virus
Noyce, R. S., Bondre, D. G., Ha, M. N., Lin, L.-T., Sisson, G., Tsao, M.-S., & Richardson, C. D. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002240 · Cited by 487
Oncolytic Viruses and Their Application to Cancer Immunotherapy
Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 408
Viral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222
Metadata
- Authors
- Russell, S. J., & Peng, K. W.
- Venue
- Current Topics in Microbiology and Immunology
- Publisher
- Springer Berlin Heidelberg
- Published
- 2008-10-30
- Volume
- 330
- Pages
- 213-241
- ISSN
- 0070-217X (ISSN-L)
- OpenAlex
- W103845142
- Cited by
- 172
- References
- 1
- FWCI
- 17.60
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measles Virus for Cancer Therapy. https://app.cochat.ai/papers/10.1007/978-3-540-70617-5_11
- The paper
- Russell, S. J., & Peng, K. W. (2008). Measles Virus for Cancer Therapy. Current Topics in Microbiology and Immunology. https://doi.org/10.1007/978-3-540-70617-5_11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.